Table 2

Outcome data from the prospective stroke trials

TrialTICI/TIMI 2 or 3 revascularizationGood outcome (mRS 0–2) at 90 days (%)Mortality at 90 days (%)Hemorrhage (symptomatic, total)
NINDS,* 19952NR43176%, 11%
NR27211%, 4%
PROACT II, 19991166%‡402510%, 35%
IMS I, 20041056%43166%, 49%
MERCI, 20051446%28448%, 28%
IMS II, 20071273% ‡461610%, 42%
Multi-MERCI, 20081355%363410%, 31%
Penumbra, 20091582% ‡253311%, 28%
RECOST, 20111688%54122%, 14%
SARIS, 2009,6 20117100%‡55†35†5%, 10%
SWIFT, 201217 1980%‡36172%, NR
START, 2012886%‡48295%, 19%
TREVO, 2012992%‡55225%, NR
TREVO 2, 201218 2086%‡40337%, NR
  • Data from TREVO 2 and SWIFT are from conference presentations.

  • *Combined results of all patients treated between 0 and 180 min.

  • †Outcome and mortality data provided is at 180 days.

  • ‡Indicates use of a core laboratory for determining TICI/TIMI revascularization.

  • mRS, modified Rankin scale; NR, not reported; TICI, Thrombolysis in Cerebral Ischemia; TIMI, Thrombolysis in Myocardial Ischemia.